Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Patent metadata

Field	Value
Publication number	US-9896444-B2
Application number	US-201615075620-A
Country	US
Kind code	B2
Filing date	Mar 21, 2016
Priority date	May 15, 2012
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The present invention relates to compounds of formula (I):

in which Y, Y 1 , R 1 , R 2 , R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

First claim

We claim:

1. A compound of formula (Ic):

in which:
R 3 is selected from hydrogen and halo;
R 4 is selected from SF 5 and —Y 2 —CF 2 —Y 3 ;
R 6 at each occurrence is independently selected from hydrogen, hydroxy, methyl, methoxy, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl;
R 7 at each occurrence is selected from hydroxy, halo, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form cyclopropyl;
Y 1 is N;
Y 2 is selected from CF 2 , O and S(O) 0-2 ;
Y 3 is selected from hydrogen, fluoro, chloro, methyl, difluoromethyl and trifluoromethyl; or
the pharmaceutically acceptable salts thereof.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from:

3. A compound of formula (Ie):

in which:
R 3 is selected from hydrogen and halo;
R 4 is selected from —SF 5 and —Y 2 —CF 2 —Y 3 ;
R 6 at each occurrence is independently selected from hydrogen, hydroxy, methyl, methoxy, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl and cyclopropyl; each
R 7 is independently selected from fluoro, hydroxy, amino, methoxy and amino-methyl;
Y 1 is N;
Y 2 is selected from CF 2 , O and S(O) 0-2 ;
Y 3 is selected from hydrogen, fluoro, chloro, methyl, difluoromethyl and trifluoromethyl; or
the pharmaceutically acceptable salts thereof.

4. A compound, or a pharmaceutically acceptable salt thereof, selected from:

5. A pharmaceutical composition comprising a compound of claim 1 , admixed with at least one pharmaceutically acceptable excipient selected from the group consisting of corn starch, potato starch, tapioca starch, starch paste, pre-gelatinized starch, sugars, gelatin, natural gums, synthetic gums, sodium alginate, alginic acid, tragacanth, guar gum, cellulose, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethylcellulose, methyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium aluminum silicate, polyvinyl pyrrolidone, talc, calcium carbonate, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, agar-agar, sodium carbonate, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, clays, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, sodium lauryl sulfate, hydrogenated vegetable oil, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, soybean oil, zinc stearate, sodium oleate, ethyl oleate, ethyl laureate, silica, and combinations thereof.

Assignees

• Furet Pascal
• Grotzfeld Robert Martin
• Jahnke Wolfgang
• Jones Darryl
• Manley Paul William
• Marzinzik Andreas
• Pelle Xavier Francois Andre
• Salem Bahaa
• Schoepfer Joseph
• Novartis Ag

Inventors

• Furet Pascal
• Grotzfeld Robert Martin
• Jahnke Wolfgang
• Jones Darryl
• Manley Paul William
• Marzinzik Andreas
• Pelle Xavier Francois Andre
• Salem Bahaa
• Schoepfer Joseph

Classifications

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D403/10

  linked by a carbon chain containing aromatic rings · CPC title

• A61K31/4155

  non condensed and containing further heterocyclic rings · CPC title

• A61P31/12

  Antivirals · CPC title

• C07D417/10

  linked by a carbon chain containing aromatic rings · CPC title